PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS
The Pharma Data
MAY 4, 2021
billion, primarily driven by Pfizer CentreOne, Pfizer’s contract manufacturing operation, reflecting sales of legacy Upjohn products to Viatris (4) and remdesivir to Gilead Sciences Inc., 7) BNT162b2 has not been approved or licensed by the U.S. Hospital products, which grew 10% operationally to $2.3 Chantix in the U.S.,
40 
Let's personalize your content